Viewing nowCombinationJanustin Met Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.

MFDS item code 202300835 · Approved 2023.03.13 · Insurance code 665003270
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used to help control blood sugar levels in patients with type 2 diabetes. In particular, it is effective in managing blood sugar when taken in combination with a diet and exercise regimen along with sitagliptin and metformin. This helps maintain stable blood sugar levels and prevents complications. It effectively treats diabetes through consistent use and lifestyle changes.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for patients who cannot achieve adequate glycemic control with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this drug in patients previously treated with other oral antihyperglycemic agents. Any change in treatment for type 2 diabetes mellitus may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, provided that the following dose adjustment is made. Treatment should not be initiated with this drug, because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains two components: sitagliptin and metformin. Sitagliptin is a medication that helps regulate blood sugar, but it may rarely cause serious allergic reactions. Such reactions can occur within three months of starting the medication, so if symptoms such as skin rash or difficulty breathing appear, you should immediately stop taking the medication and consult a physician. In addition, sitagliptin may cause inflammation of the pancreas, known as pancreatitis. If symptoms such as abdominal pain, vomiting, or fever occur, immediate medical attention is required. Metformin is primarily excreted through the kidneys; therefore, it should not be administered to patients with poor kidney function, and its use should be avoided in cases of severe infection, dehydration, or heart failure which could affect kidney function. During the use of this medication, there is a rare but serious metabolic complication called lactic acidosis, which can occur, so if sudden symptoms such as difficulty in breathing, muscle pain, fatigue, or abdominal pain develop, you must inform healthcare personnel immediately. This medication may also cause hypoglycemia, so caution is advised if meals are skipped or vigorous exercise is undertaken, and the risk of hypoglycemia may increase when taken in conjunction with other blood sugar-lowering medications. When undergoing surgery or examinations that involve the use of radiocontrast agents, this medication should be temporarily discontinued, and kidney function tests should be performed before resuming the medication. It is advisable not to use this medication in pregnant women or those likely to become pregnant, nursing mothers, or children under the age of 18. While taking this medication, regular checks of kidney function and blood tests should be conducted to monitor for any abnormalities, and alcohol consumption should be avoided. Lastly, this medication may interact with certain drugs, so if you are taking other medications, it is essential to inform your doctor or pharmacist.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering. It is best to maintain a storage temperature between 1 degree and 30 degrees Celsius. Doing so will help preserve the medication's effectiveness and prevent degradation.
Red-brown oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungbo Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.